1. Comment on ’Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial’
- Author
-
Mojtaba Varshochi, Akbar Sharifi, Mehdi Maleki, Azam Esmailnajad, Armin Sadeghi, Ali Taghizadieh, Khalil Ansarin, Parviz Saleh, Ramin Zand, Masoud Ahangari Maleki, Zahra Soroureddin, Niusha Kalami, Haleh Rezaee, Mehdi Haghdoost, Masoud Nouri-Vaskeh, Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Université de Rennes 1 - Faculté des sciences pharmaceutiques et biologiques (UR1 Pharmacie), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes - Faculté des sciences pharmaceutiques et biologiques (UR Pharmacie), and Université de Rennes (UR)
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,[SDV]Life Sciences [q-bio] ,Blood Pressure ,030204 cardiovascular system & hematology ,Losartan ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,Humans ,Medicine ,030212 general & internal medicine ,Amlodipine ,Antihypertensive Agents ,ComputingMilieux_MISCELLANEOUS ,030304 developmental biology ,Aged ,Aged, 80 and over ,0303 health sciences ,Original Paper ,SARS-CoV-2 ,business.industry ,Mortality rate ,COVID-19 ,General Medicine ,Middle Aged ,Original Papers ,3. Good health ,Icu admission ,Clinical trial ,Infectious Diseases ,Treatment Outcome ,Blood pressure ,Hypertension ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID‐19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID‐19. Methods In this randomised clinical trial, hospitalised patients with COVID‐19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30‐day mortality rate and length of hospital stay. Results The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value = .068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value = .994). The 30‐day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = .241). Conclusions There was no priority in losartan or amlodipine administration in COVID‐19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first‐line anti‐HTN medications in COVID‐19.
- Published
- 2021